标题
Targeting c-MET by LY2801653 for treatment of cholangiocarcinoma
作者
关键词
-
出版物
MOLECULAR CARCINOGENESIS
Volume 55, Issue 12, Pages 2037-2050
出版商
Wiley
发表日期
2016-01-12
DOI
10.1002/mc.22449
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Transcription Factor STAT3 as a Novel Molecular Target for Cancer Prevention
- (2014) Ailian Xiong et al. Cancers
- A Critical Role for Notch Signaling in the Formation of Cholangiocellular Carcinomas
- (2013) Steffen Zender et al. CANCER CELL
- Dramatic Antitumor Effects of the Dual MET/RON Small-Molecule Inhibitor LY2801653 in Non-Small Cell Lung Cancer
- (2013) I. Kawada et al. CANCER RESEARCH
- Inhibition of Tumor Growth and Metastasis in Non-Small Cell Lung Cancer by LY2801653, an Inhibitor of Several Oncokinases, Including MET
- (2013) W. Wu et al. CLINICAL CANCER RESEARCH
- Targeting the HGF/c-MET Pathway in Hepatocellular Carcinoma
- (2013) L. Goyal et al. CLINICAL CANCER RESEARCH
- RAC1: An Emerging Therapeutic Option for Targeting Cancer Angiogenesis and Metastasis
- (2013) H. K. Bid et al. MOLECULAR CANCER THERAPEUTICS
- Activation of Notch Signaling Is Required for Cholangiocarcinoma Progression and Is Enhanced by Inactivation of p53 In Vivo
- (2013) Mona El Khatib et al. PLoS One
- Inhibition of hedgehog signaling attenuates carcinogenesisin vitroand increases necrosis of cholangiocellular carcinoma
- (2012) Mona El Khatib et al. HEPATOLOGY
- LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models
- (2012) S. Betty Yan et al. INVESTIGATIONAL NEW DRUGS
- Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma
- (2011) M Miyamoto et al. BRITISH JOURNAL OF CANCER
- c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma
- (2011) Hanning You et al. HEPATOLOGY
- Risk factors for cholangiocarcinoma
- (2011) Gia L. Tyson et al. HEPATOLOGY
- BRAFV600E: Implications for Carcinogenesis and Molecular Therapy
- (2011) E. R. Cantwell-Dorris et al. MOLECULAR CANCER THERAPEUTICS
- Epidemiological trends in incidence and mortality of hepatobiliary cancers in Germany
- (2011) Thomas von Hahn et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- An overview of the c-MET signaling pathway
- (2011) Shawna Leslie Organ et al. Therapeutic Advances in Medical Oncology
- c-MET as a potential therapeutic target and biomarker in cancer
- (2011) J. Rafael Sierra et al. Therapeutic Advances in Medical Oncology
- p21Waf1is required for cellular senescence but not for cell cycle arrest induced by the HDAC inhibitor sodium butyrate
- (2010) Vasily S. Romanov et al. CELL CYCLE
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
- (2010) Juan Valle et al. NEW ENGLAND JOURNAL OF MEDICINE
- New insights on cholangiocarcinoma
- (2010) Manuela Gatto World Journal of Gastrointestinal Oncology
- PHA665752, a small-molecule inhibitor of c-Met, inhibits hepatocyte growth factor-stimulated migration and proliferation of c-Met-positive neuroblastoma cells
- (2009) Hal E Crosswell et al. BMC CANCER
- HGF and c-Met Participate in Paracrine Tumorigenic Pathways in Head and Neck Squamous Cell Cancer
- (2009) L. M. Knowles et al. CLINICAL CANCER RESEARCH
- Drug development of MET inhibitors: targeting oncogene addiction and expedience
- (2008) Paolo M. Comoglio et al. NATURE REVIEWS DRUG DISCOVERY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now